Current ART, Virologic Failure and Implications for HIV Drug Resistance, 2nd Edition

Dear Colleagues,

Virologic failure is the term used by physicians, clinicians, and clinical virologists to describe the failure to suppress and/or maintain virus replication at undetectable levels within a patient receiving antiretroviral therapy (ART). Identifying and managing the determinants of virological failure have an important role in facilitating high treatment success, improving quality of life for patients, and increasing survival rate from treatment failure(s). Whilst identifying the determinants of virologic failure is perceived as relatively straightforward with earlier versions of ART (especially in terms of drug resistance), there are few descriptions of virologic failure and acquired drug resistance with more contemporary ART. Understanding the concept and risk of virologic failure in terms of both conventional and contemporary ART is of paramount importance in order to make the next great leap in treating people living with HIV: permanent viral suppression without the need for lifelong medications.  

This Special Issue will accept many forms of manuscripts (original research papers, short communications, reviews, and opinion pieces) focusing on the current understanding of virological failure risk and the implications for drug resistance in the context of contemporary ART strategies.

Dr. Susan M. Schader
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.